<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939142</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-010-MM-002</org_study_id>
    <nct_id>NCT04939142</nct_id>
  </id_info>
  <brief_title>A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)</brief_title>
  <acronym>BENCH</acronym>
  <official_title>A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antengene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010,&#xD;
      Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with&#xD;
      Relapsed or Refractory Multiple Myeloma (RRMM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010,&#xD;
      Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with&#xD;
      Relapsed or Refractory Multiple Myeloma (RRMM). About 150 subjects are planned to be enrolled&#xD;
      in this study, and be randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd&#xD;
      Arm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>To evaluate progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>The estimates of Kaplan-Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>To evaluate duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>evaluated by IRC (PR + VGPR + CR + sCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS2)</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>PFS after further treatment followed by treatment with SVd/Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to remission(TTR)</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>To compare the efficacy of treatment with SVd and Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VGPR+CR+sCR</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>Proportion of subjects of VGPR + CR + sCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Three years after last patient first dose</time_frame>
    <description>Incidence of any Grade ≥ 2 peripheral neuropathy events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>SVd (Selinexor+Bortezomib+dexamethasone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vd(Bortezomib+dexamethasone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-010</intervention_name>
    <description>Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm):&#xD;
SVd Arm (~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)&#xD;
Vd Arm (~50): Bortezomib (Cycles 1-8 [BIW], Cycles ≥ 9 [QW]) + dexamethasone (Cycles 1-8 [Four times a week], Cycles ≥ 9 [BIW])</description>
    <arm_group_label>SVd (Selinexor+Bortezomib+dexamethasone)</arm_group_label>
    <arm_group_label>Vd(Bortezomib+dexamethasone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand and voluntarily sign an informed consent form (ICF).&#xD;
&#xD;
          2. Age ≥ 18 years.&#xD;
&#xD;
          3. Confirmed MM with measurable disease per IMWG guidelines, and meet at least 1 of the&#xD;
             following:&#xD;
&#xD;
               1. Serum M-protein ≥ 0.5 g/dL (&gt; 5 g/L) by serum protein electrophoresis (SPEP) or&#xD;
                  for immunoglobulin IgA, IgD myeloma, replaced by quantitative serum IgA, IgD&#xD;
                  levels; or&#xD;
&#xD;
               2. Urinary M-protein level ≥ 200 mg/24 hours; or&#xD;
&#xD;
               3. Serum FLC ≥ 100 mg/L, provided that the serum FLC ratio is abnormal (Normal FLC&#xD;
                  ratio: 0.26 to 1.65).&#xD;
&#xD;
          4. Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens.&#xD;
             Induction therapy followed by stem cell transplant and consolidation/maintenance&#xD;
             therapy will be considered as 1 anti-MM regimen.&#xD;
&#xD;
          5. Valid evidence of progressive MM (based on the Investigator's determination according&#xD;
             to the IMWG response criteria) on or after their last regimen.&#xD;
&#xD;
          6. Must have an ECOG Status score of 0, 1, or 2.&#xD;
&#xD;
          7. Renal function should meet the following criteria: creatinine clearance [CrCl] rates ≥&#xD;
             20 mL/min (Calculated using the formula of Cockroft and Gault).&#xD;
&#xD;
          8. Resolution of any clinically significant non-hematological toxicities (If any) from&#xD;
             previous treatments to Grade ≤1 or baseline by C1D1. Subject with chronic, stable&#xD;
             Grade 2 non hematological toxicities may be included following approval from the&#xD;
             Medical Monitor.&#xD;
&#xD;
          9. Female subjects of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening. Female subjects of childbearing potential and fertile male subjects must&#xD;
             use highly effective methods of contraception throughout the study and for 3 months&#xD;
             following the last dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior exposure to SINE compounds (Including ATG-010), or suspected allergy to SINE or&#xD;
             similar drugs.&#xD;
&#xD;
          2. Active plasma cell leukemia.&#xD;
&#xD;
          3. Documented systemic light chain amyloidosis.&#xD;
&#xD;
          4. MM involving the central nervous system.&#xD;
&#xD;
          5. POEMS syndrome (Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,&#xD;
             and skin changes).&#xD;
&#xD;
          6. Spinal cord compression related to MM.&#xD;
&#xD;
          7. Greater than Grade 2 peripheral neuropathy or Grade ≥ 2 peripheral neuropathy with&#xD;
             pain at baseline, regardless of whether the subject is currently receiving medication.&#xD;
&#xD;
          8. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.&#xD;
&#xD;
          9. Active graft versus host disease (After allogeneic stem cell transplantation) at&#xD;
             screening.&#xD;
&#xD;
         10. Uncontrolled active infections requiring intravenous antibiotics, antivirals, or&#xD;
             antifungal therapy in 2 weeks prior to C1D1.&#xD;
&#xD;
         11. Major surgery within 4 weeks prior to C1D1.&#xD;
&#xD;
         12. Known active human immunodeficiency virus (HIV) infection or HIV seropositivity.&#xD;
&#xD;
         13. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C&#xD;
             virus ribonucleic acid (RNA) or hepatitis B virus deoxyribonucleic acid (HBV-DNA).&#xD;
&#xD;
         14. Pregnant or lactating women.&#xD;
&#xD;
         15. Life expectancy of &lt; 4 months.&#xD;
&#xD;
         16. Any active gastrointestinal dysfunction interfering with the subject's ability to&#xD;
             swallow tablets, or any active gastrointestinal dysfunction that could interfere with&#xD;
             absorption of study treatment.&#xD;
&#xD;
         17. Any active, serious psychiatric, medical, or other conditions/situations that, in the&#xD;
             opinion of the Investigator, could interfere with treatment, compliance, or the&#xD;
             ability to give informed consent.&#xD;
&#xD;
         18. Contraindication to any of the required concomitant drugs or supportive treatments.&#xD;
&#xD;
         19. Any diseases or complications which may interfere with the study procedures.&#xD;
&#xD;
         20. Subject unwilling or unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Lu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimin Sun, MD</last_name>
    <phone>13701803117</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chengjun Gu, MD</last_name>
    <phone>18030488403</phone>
    <email>chengjun.gu@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingshu Zeng, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Qingshu Zeng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affilate Hospital OF USTC</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liangquan Geng, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Liangquan Geng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100043</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wen Gao, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Wen Gao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People'S Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Lu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jin Lu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xi Zhang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xi Zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People'S Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianyu Weng, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jianyu Weng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhongjun Xia, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhongjun Xia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongqiang Wei, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yongqiang Wei, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Second People'S Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Du, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xin Du, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baijun Fang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Baijun Fang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianfeng Zhou, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jianfeng Zhou, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanjuan He, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yanjuan He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Liu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jing Liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bing Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bing Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijuan Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lijuan Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sshengjing Hospital China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhuogang Liu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhuogang Liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Wei Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>v</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuping Zhong, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yuping Zhong, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shangdong University</name>
      <address>
        <city>Jinan</city>
        <state>Shangdong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Hou, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ming Hou, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shangdong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xin Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>09022836</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Hou, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jian Hou, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weijun Fu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Weijun Fu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianqing Mi, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jianqing Mi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Liu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Peng Liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chungkang Chang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Chungkang Chang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaobing Huang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xiaobing Huang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rong Fu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rong Fu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yafei Wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yafei Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhen Cai, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhen Cai, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

